3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Colorectal Neoplasms
5
Medulloblastoma
3
Colonic Neoplasms
3
Turcot syndrome
2
Triple Negative Breast Neoplasms
2
Rhabdoid Tumor
2
Recurrence
2
Pinealoma
2
Neuroblastoma
2
Ependymoma
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Solid Tumor
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pyloric Stenosis, Hypertrophic
1
Pancreatic Cancer Metastatic
1
Ovarian Neoplasms
1
Osteosarcoma
1
Oropharyngeal Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Locally Advanced Rectal Cancer
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
7
X-Rays
6
Specimen Handling
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
ulixertinib
2
trametinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
dabrafenib
2
LY3023414
2
olaparib
1
etoposide phosphate
1
cobimetinib
1
Vemurafenib
1
Sirolimus
1
Pharmacogenomic Variants
1
Lenalidomide
1
Genetic Testing
1
Etoposide
1
Cyclophosphamide
1
Celecoxib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Histiocytosis, Langerhans-Cell
×
Celecoxib
×
1 year
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled